- Home
- FDBC vs PBYI Comparison
FDBC vs PBYI Comparison
Compare FDBC & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FDBC
- PBYI
- Stock Information
- Founded
- FDBC 1902
- PBYI 2010
- Country
- FDBC United States
- PBYI United States
- Employees
- FDBC N/A
- PBYI N/A
- Industry
- FDBC Major Banks
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- FDBC Finance
- PBYI Health Care
- Exchange
- FDBC Nasdaq
- PBYI Nasdaq
- Market Cap
- FDBC 234.2M
- PBYI 237.2M
- IPO Year
- FDBC N/A
- PBYI N/A
- Fundamental
- Price
- FDBC $42.31
- PBYI $5.31
- Analyst Decision
- FDBC
- PBYI Strong Buy
- Analyst Count
- FDBC 0
- PBYI 1
- Target Price
- FDBC N/A
- PBYI $7.00
- AVG Volume (30 Days)
- FDBC 9.7K
- PBYI 500.1K
- Earning Date
- FDBC 10-27-2025
- PBYI 11-06-2025
- Dividend Yield
- FDBC 3.88%
- PBYI N/A
- EPS Growth
- FDBC 49.33
- PBYI 434.29
- EPS
- FDBC 4.10
- PBYI 0.97
- Revenue
- FDBC $84,975,000.00
- PBYI $238,062,000.00
- Revenue This Year
- FDBC N/A
- PBYI N/A
- Revenue Next Year
- FDBC N/A
- PBYI N/A
- P/E Ratio
- FDBC $10.07
- PBYI $5.44
- Revenue Growth
- FDBC 20.65
- PBYI 8.63
- 52 Week Low
- FDBC $37.00
- PBYI $2.32
- 52 Week High
- FDBC $61.21
- PBYI $6.07
- Technical
- Relative Strength Index (RSI)
- FDBC 42.10
- PBYI 64.65
- Support Level
- FDBC $41.72
- PBYI $5.11
- Resistance Level
- FDBC $43.85
- PBYI $5.42
- Average True Range (ATR)
- FDBC 0.58
- PBYI 0.23
- MACD
- FDBC -0.27
- PBYI 0.06
- Stochastic Oscillator
- FDBC 21.89
- PBYI 88.34
About FDBC Fidelity D & D Bancorp Inc.
Fidelity D & D Bancorp Inc is a bank holding company. Through its wholly-owned state-chartered commercial bank subsidiary, The Fidelity Deposit and Discount Bank (the Bank), it offers a full range of traditional banking services. The Bank has a personal and corporate trust department and also provides alternative financial and insurance products with asset management services. Its primary market areas are Lackawanna, Luzerne and Northampton Counties, Pennsylvania. The company's primary deposit products are demand deposits and interest-bearing time, money market and savings accounts. It offers a full array of loan products to meet the needs of retail and commercial customers. Company includes segments: Commercial and Industrial, Commercial Real Estate, Consumer, Residential Real Estate.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.